TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01857934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Transplantation of previously harvested peripheral blood stem cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cell infusion
Description: Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
Study: NCT03486236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-440
Description: VX-440 was administered in TC with TEZ and IVA.
Study: NCT03702920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard medical treatment according to the institution's standard practice
Study: NCT01857934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given subcutaneously (SQ)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given subcutaneously (SQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interleukin-2
Description: Given by continuous infusion during MRD maintenance, and SQ during induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given orally (PO)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study: NCT02361905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 5 mg/day will be administered starting from day 1 of the cycle and up to three months later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
Study: NCT02220647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC
Study: NCT03997201

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ripple Mapping guided ischaemic VT ablation
Description: Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue.
Study: NCT01460771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS (Transcranial Direct-current Stimulation)
Description: active TDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TDCS (Transcranial Direct-current Stimulation)
Description: TDCS at 0mA
Study: NCT02220647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT03505463

Intervention type: OTHER
Intervention: Blood samples
Description: Three blood samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques.

Intervention type: OTHER
Intervention: Blood samples
Description: Three blood samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques.

Intervention type: OTHER
Intervention: Cerebrospinal fluid sample
Description: Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques.

Intervention type: OTHER
Intervention: Cerebrospinal fluid sample
Description: Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are \<72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques.

Intervention type: OTHER
Intervention: Clinical examination
Description: Clinical examinations will be performed at \<72 hours, 7 days and 365 days post-injury.
Study: NCT00541775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Rosiglitazone
Description: Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
Study: NCT01815320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CE-US)
Study: NCT00541775

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Metformin
Description: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
Study: NCT01815320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoVue
Study: NCT00541775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Metformin
Description: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
Study: NCT02291250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrants with polycal OGTT
Description: Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups
Study: NCT00541775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Metformin
Description: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
Study: NCT02291250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greencurrants with polycal OGTT
Description: Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrants with glucose OGTT
Description: Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups
Study: NCT02368509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perform sensory tests

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Perform sensory tests
Study: NCT03853200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMix Root Canal Irrigant
Description: Endodontic irrigant recommended for final irrigation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17%EDTA+2%Chlorhexidine
Description: two endodontic irrigants will be used in this group in a sequential manner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDTA
Description: 17% EDTA irrigation solution
Study: NCT03945110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iAluRil® intravesical instillations
Description: 50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.
Study: NCT03590327

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: rTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: rTMS
Study: NCT02939781

Intervention type: DEVICE
Intervention: Indirect calorimetry
Description: Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
Study: NCT01915147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXN PR followed by OxyPR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyPR followed by OXN PR tablets
Study: NCT01645332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DLBS3233
Description: Placebo of DLBS3233 once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Description: 100 mg DLBS3233 once daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle modification
Description: Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
Study: NCT03109197

Intervention type: OTHER
Intervention: Biospecimin Collection

Intervention type: OTHER
Intervention: Biospecimin Collection
Study: NCT02723279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPNS
Description: Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT
Description: Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
Study: NCT02862275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection
Study: NCT03486236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
Study: NCT00954655

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: polymorphism analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT02342951

Intervention type: OTHER
Group type: OTHER
Intervention: Lung clearance index determination
Description: Lung clearance index determination
Study: NCT04450875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group (with diet)
Description: Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.
Study: NCT00373087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entacapone
Description: entacapone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l dopa versus placebo
Description: l dopa versus placebo
Study: NCT01220063

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: 10 Gy for 4 times (total 40 Gy)

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: 40 mg/m² : Day 1 and day 8
Study: NCT03486236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebos
Description: Placebos matched to VX-440, TEZ, and IVA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebos
Description: Placebos matched to VX-440, TEZ, and IVA.
Study: NCT01770184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Study: NCT02574221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride toothpaste
Description: 0.454% stannous fluoride toothpaste

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: cavity protection toothpaste
Description: 0.243% sodium fluoride toothpaste
Study: NCT02677779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: Single session of CO2 laser debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional surgery
Description: Single session of traditional debridement
Study: NCT01479725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HBOT
Description: HBOT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HBOT
Description: HBOT
Study: NCT03818815

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: OP0201
Description: OP0201 20mg per day in two divided doses for 10 days

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0mg per day in two divided doses for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Oral Amoxicillin-clavulanate in two divided doses for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Oral Amoxicillin-clavulanate in two divided doses for 10 days
Study: NCT00262405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zileuton

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine/prednisone
Study: NCT00756002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
Study: NCT01442584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian transplantation
Description: ovarian transplantation
Study: NCT03405103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Striving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Boning-Up

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Personal Choice
Study: NCT01029561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Treatment with Continuous Positive Airway Pressure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Conventional diet treatment that undergo patients in the Bariatric Surgery Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Conventional diet treatment that undergo patients in the Bariatric Surgery Program
Study: NCT02214589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose, facilitated tucking, NNS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose and NNS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated tucking and NNS
Study: NCT03623750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGF-PTI
Description: The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
Study: NCT00298532

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Advanced Life Support
Study: NCT02928497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN LAAC Device Implant
Description: WATCHMAN LAAC Implant
Study: NCT04589767

Intervention type: BEHAVIORAL
Intervention: CAPD scale
Description: Two nurses will apply CAPD scale. One nurse will repeat the CAPD evaluation two minutes later
Study: NCT02962557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake
Description: The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
Study: NCT01888588

Intervention type: DRUG
Intervention: Risk of symptomatic peptic ulcer
Description: Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use

Intervention type: DRUG
Intervention: Risk of symptomatic peptic ulcer
Description: Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
Study: NCT02732730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: 400 women who accept to initiate PrEP
Study: NCT01651598

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 144807
Description: multiple dose (bid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: multiple dose (bid, low to high dose)
Study: NCT01163656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller Laryngoscope
Description: Device is used to facilitate tracheal intubation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Cobalt Video Laryngoscopes
Description: The laryngoscope design with the integration of video technology into the laryngoscope blade.